Literature DB >> 23563416

Building for big pharma.

Asiya Giniatullina1, Marco Boorsma, Geert-Jan Mulder, Sander van Deventer.   

Abstract

Mesh：

Year:  2013        PMID： 23563416     DOI： 10.1038/nbt.2533

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin.

Authors:  David Nutt; Guy Goodwin
Journal:  Eur Neuropsychopharmacol       Date:  2011-07       Impact factor: 4.600
  1 in total
  4 in total

1.  Trade-sale exits in different biotech sectors.

Authors:  Kenneth Fernald; Eric Claassen
Journal:  Nat Biotechnol       Date:  2015-12-09       Impact factor: 54.908

2.  Acquiring orphans.

Authors:  Rogier Rooswinkel; Geert-Jan Mulder; Sander van Deventer
Journal:  Nat Biotechnol       Date:  2014-03       Impact factor: 54.908

3.  Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors.

Authors:  Daniel Tobias Michaeli; Hasan Basri Yagmur; Timur Achmadeev; Thomas Michaeli
Journal:  Ther Innov Regul Sci       Date:  2022-01-11       Impact factor: 1.778

4.  Value drivers of development stage biopharma companies.

Authors:  Daniel Tobias Michaeli; Hasan Basri Yagmur; Timur Achmadeev; Thomas Michaeli
Journal:  Eur J Health Econ       Date:  2022-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.